Intercept to go back to FDA with its NASH treatment application https://ift.tt/mjGQWty

The FDA declined to approve the therapy in 2020, saying the predicted benefit remains uncertain and does not sufficiently outweigh the potential risks. At the time, the FDA recommended Intercept submit additional data from the late-stage study.

from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/NvP8pZd